Combination of two pharmaceuticals may prove effective in the treatment of MS
A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects.
To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer (Max Planck Research Unit for Enzymology of Protein Folding, Halle/Saale, Germany) and Dr. Frank Striggow (German Center for Neurodegenerative Diseases (DZNE)) have combined two already approved pharmaceutical substances with each other using a chemical linker structure.
The objectives of this combination are to ensure maximum brain cell protection on the one hand and the suppression of unwanted side effects on the other.
The new class of substances has now been registered with the European Patent Office as the DZNE's first patent in the form of a joint patent application with the Max Planck Research Unit. "The patent approval process can take several years. During this phase we are planning to conclude the pre-clinical development. It is our aim to start with clinical research and development at the earliest possible time. Overall, we have identified substantial therapeutic potential as far as chronic and age-related neurodegenerative diseases are concerned," comments Dr. Frank Striggow. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2479